News
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
7h
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, ...
Explore more
US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...
Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...
8h
MarketBeat on MSNAre Growth Stocks Back? 3 That Look Like Winners to Buy NowIn today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...
Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – ...
In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...
Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results